Golden Heart Flower
Disease-modifying Medicines for Glycogen Storage Diseases
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in May 2018 by Shlomi Schneider and Adi Moreh, Golden Heart Flower operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing new approaches to treat rare diseases.
Business overview
Golden Heart Flower is an early-stage pharmaceutical company dedicated to developing disease-modifying medicines for rare conditions, specifically Glycogen Storage Diseases (GSDs) and Lysosomal Storage Diseases (LSDs). The company's core technology is centered on novel therapeutic approaches within the biopharmaceutical sector, operating in the Health Tech & Life Sciences industry with a focus on drug discovery and development.
Log in to access full profile ›Company Intelligence Q&A
- What is Golden Heart Flower's primary focus?
- Golden Heart Flower is an early-stage pharmaceutical company focused on developing new approaches to treat rare diseases, including Glycogen Storage Diseases (GSDs) and Lysosomal Storage Diseases (LSDs).
- When was Golden Heart Flower founded?
- Golden Heart Flower was founded in May 2018.
- Who are the founders of Golden Heart Flower?
- The co-founders of Golden Heart Flower are Shlomi Schneider and Adi Moreh.
- What is the current employee count for Golden Heart Flower?
- Golden Heart Flower currently has 1–10 employees.
- In which sector does Golden Heart Flower primarily operate?
- Golden Heart Flower operates primarily in the Health Tech & Life Sciences sector, specifically within Pharma & Medical Biotechnology and Drugs Discovery & Development.